Bayer hits back over Indian complusory licence ruling
German pharmaceutical company Bayer says it will appeal yesterday’s decision by India’s IP Appellate Board to uphold a compulsory licence granted over its cancer drug Nexavar
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
